Similarly, next-generation IL-15-armored, FAP-targeting CAR-iNKT therapy MiNK-215, designed to target the tumor stroma, further enhanced endogenous anti-tumor activity in human organoid models of treatment-resistant colorectal cancer liver metastases (22, 100, 101). This evidence concerns the gene FAP and colorectal cancer.